Dieter Mayer

Dieter Mayer

Auto-generated profile, based on publicly available information

Dieter Mayer

Department of Dermatology University Hospital of Zurich Zurich Switzerland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
AAAfsaneh Alavi
Afsaneh Alavi
RSR. Gary Sibbald
R. Gary Sibbald
DMDieter Mayer
Dieter Mayer
LGLaurie Goodman
Laurie Goodman
MBMariam Botros
Mariam Botros
RKRobert S. Kirsner
Robert S. Kirsner

21 December 2017 in Skin Pharmacology and Physiology
Verified
Journal Article
Open access
PDF file
AKAxel Kramer
Axel Kramer
JDJoachim Dissemond
Joachim Dissemond
SKSimon Kim
Simon Kim
CWChristian Willy
Christian Willy
DMDieter Mayer
Dieter Mayer
OAOjan Assadian
Ojan Assadian
Wound antisepsis has undergone a renaissance due to the introduction of highly effective wound-compatible antimicrobial agents and the spread of multidrug-resistant organisms (MDROs). However, a strict indication must be set for the application of these agents. An infected or critically colonized wound must be treated antiseptically. In addition, systemic antibiotic therapy is required in case the infection spreads. If applied preventively, the Wounds-at-Risk Score allows an assessment of the risk for infection and thus appropriateness of the indication. The content of this updated consensus recommendation still largely consists of discussing properties of octenidine dihydrochloride (OCT), polihexanide, and iodophores. The evaluations of hypochlorite, taurolidine, and silver ions have been updated. For critically colonized and infected chronic wounds as well as for burns, polihexanide is classified as the active agent of choice. The combination 0.1% OCT/phenoxyethanol (PE) solution is suitable for acute, contaminated, and traumatic wounds, including MRSA-colonized wounds due to its deep action. For chronic wounds, preparations with 0.05% OCT are preferable. For bite, stab/puncture, and gunshot wounds, polyvinylpyrrolidone (PVP)-iodine is the first choice, while polihexanide and hypochlorite are superior to PVP-iodine for the treatment of contaminated acute and chronic wounds. For the decolonization of wounds colonized or infected with MDROs, the combination of OCT/PE is preferred. For peritoneal rinsing or rinsing of other cavities with a lack of drainage potential as well as the risk of central nervous system exposure, hypochlorite is the superior active agent. Silver-sulfadiazine is classified as dispensable, while dyes, organic mercury compounds, and hydrogen peroxide alone are classified as obsolete. As promising prospects, acetic acid, the combination of negative pressure wound therapy with the instillation of antiseptics (NPWTi), and cold atmospheric plasma are also subjects of this assessment.

1 December 2014 in Circulation
Verified
Journal Article
Closed access
KSKarl Sörelius
Karl Sörelius
KMKevin Mani
Kevin Mani
MBMartin Björck
Martin Björck
PSPetr Sedivy
Petr Sedivy
CWCarl-Magnus Wahlgren
Carl-Magnus Wahlgren
AWAnders Wanhainen
Anders Wanhainen
Background—: Mycotic aortic aneurysm (MAA) is a rare and life-threatening disease. The aim of this European multicenter collaboration was to study the durability of endovascular aortic repair (EVAR) of MAA, by assessing late infection–related complications and long-term survival. Methods and Results—: All EVAR treated MAAs, between 1999 and 2013 at 16 European centers, were retrospectively reviewed. One hundred twenty-three patients with 130 MAAs were identified. Mean age was 69 years (range 39–86), 87 (71%) were men, 58 (47%) had immunodeficiency, and 47 (38%) presented with rupture. Anatomic locations were ascending/arch (n=4), descending (n=34), paravisceral (n=15), infrarenal aorta (n=63), and multiple (n=7). Treatments were thoracic EVAR (n=43), fenestrated/branched EVAR (n=9), and infrarenal EVAR (n=71). Antibiotic was administered for mean 30 weeks. Mean follow-up was 35 months (range 1 week to 149 months). Six patients (5%) were converted to open repair during follow-up. Survival was 91% (95% confidence interval, 86% to 96%), 75% (67% to 83%), 55% (44% to 66%), and 41% (28% to 54%) after 1, 12, 60, and 120 months, respectively. Infection-related death occurred in 23 patients (19%), 9 after discontinuation of antibiotic treatment. A Cox regression analysis demonstrated non-Salmonella–positive culture as predictors for late infection–related death. Conclusions—: Endovascular treatment of MAA is feasible and for most patients a durable treatment option. Late infections do occur, are often lethal, and warrant long-term antibiotic treatment and follow-up. Patients with non-Salmonella–positive blood cultures were more likely to die from late infection.

1 January 2014 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
AAAfsaneh Alavi
Afsaneh Alavi
RSR. Gary Sibbald
R. Gary Sibbald
DMDieter Mayer
Dieter Mayer
LGLaurie Goodman
Laurie Goodman
MBMariam Botros
Mariam Botros
RKRobert S. Kirsner
Robert S. Kirsner

1 November 2009 in Annals of Surgery
Verified
Journal Article
Closed access
FVFrank J Veith
Frank J Veith
MLMario Lachat
Mario Lachat
DMDieter Mayer
Dieter Mayer
MMMartin Malina
Martin Malina
JHJan Holst
Jan Holst
RIRAAA Investigators
RAAA Investigators
Case and single center reports have documented the feasibility and suggested the effectiveness of endovascular aneurysm repair (EVAR) of ruptured abdominal aortic aneurysms (RAAAs), but the role and value of such treatment remain controversial. To clarify these we examined a collected experience with use of EVAR for RAAA treatment from 49 centers. Data were obtained by questionnaires from these centers, updated from 13 centers committed to EVAR treatment whenever possible and included treatment details from a single center and information on 1037 patients treated by EVAR and 763 patients treated by open repair (OR). Overall 30-day mortality after EVAR in 1037 patients was 21.2%. Centers performing EVAR for RAAAs whenever possible did so in 28% to 79% (mean 49.1%) of their patients, had a 30-day mortality of 19.7% (range: 0%–32%) for 680 EVAR patients and 36.3% (range: 8%–53%) for 763 OR patients (P < 0.0001). Supraceliac aortic balloon control was obtained in 19.1% ± 12.0% (±SD) of 680 EVAR patients. Abdominal compartment syndrome was treated by some form of decompression in 12.2% ± 8.3% (±SD) of these EVAR patients. These results indicate that EVAR has a lower procedural mortality at 30 days than OR in at least some patients and that EVAR is better than OR for treating RAAA patients provided they have favorable anatomy; adequate skills, facilities, and protocols are available; and optimal strategies, techniques, and adjuncts are employed.

1 April 2015 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
BSB.-R. Sah
B.-R. Sah
LHL. Husmann
L. Husmann
DMD. Mayer
D. Mayer
ASA. Scherrer
A. Scherrer
ZRZ. Rancic
Z. Rancic
BHBarbara Hasse
Barbara Hasse